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Cancer therapies are known to cause fertility impairment as a
long-term treatment side effect. Although postpubertal male
cancer patients have the possibility to cryopreserve semen before
gonadotoxic treatment, prepubertal boys do not yet produce
spermatozoa.1 Therefore, proposed fertility-preservation strategies
for these boys are cryopreservation of testicular tissue followed by
autotransplantation of spermatogonial stem cells, tissue grafting
or in vitro maturation.1–3 Numerous animal studies, including
those of non-human primates, have proven the successful
accelerated recovery of spermatogenesis following the application
of fertility-restoration techniques. Hence, at this moment, testi-
cular tissue cryopreservation is offered to patients as a part of
clinical research programs, while the fertility-restoration strategy
remains experimental.3
Male patients with leukaemia who are at a high risk of infertility
include those receiving allogenic haematopoietic stem cell
transplantation, while conventional chemotherapy is associated
with a low risk of infertility.4,5 Therefore, the majority of patients
with haematological malignancies do not meet the criteria for
testicular tissue cryopreservation at the time of the original
diagnosis. However, disease response or relapse may result in
patients undergoing potentially sterilizing therapy regimens. This
means that many patients with leukaemia have already received
chemotherapy before testicular tissue cryopreservation is offered.1
The potential effect of previous chemotherapy must be taken into
account when testis biopsy and storage are considered for these
patients.
In order to optimize the cryobanking of prepubertal testicular
tissue, more information on the effects of cancer therapies on
spermatogonial quantities is required. Recently, reference values
concerning spermatogonial quantity in human testes throughout
healthy prepuberty were established.6 In the present study, these
reference values were used to evaluate the effects of leukaemia
treatment on spermatogonial quantity and hence spermatogenic
recovery in prepubertal boys with acute lymphoblastic leukaemia.
The study material consisted of testis samples from prepubertal
boys with acute lymphoblastic leukaemia who had undergone
routine bilateral/unilateral testicular biopsy to examine possible
testicular leukaemia at the cessation of antileukaemia therapy at
University Central Hospitals in Helsinki and Turku between 1979
and 1995. The Research Ethics Committees of Helsinki University
Hospital (No 192/13/03/03/2013) and Turku University Hospital
(DNR 1905-32/300/05) approved the study. Altogether, 37 boys
were identiﬁed through hospital records and enrolled in the study.
Eighteen of these boys had earlier been included in a study to
evaluate the expression of spermatogonial markers during
leukaemia therapy, as previously described.7 Testicular biopsies
were performed at the end of the treatment, during the last days
of the per oral maintenance therapy. Four of the 37 boys were
subjected to two biopsies—one at the end of induction therapy
(50 days after diagnosis) and a second biopsy at the end of the
treatment (Figure 1). Antileukaemia therapy was carried out as
described earlier.8,9 Brieﬂy, the therapy involved the use of
antimetabolites, vinca-alkaloids and anthracyclines. Of the 37
patients, 15 received prophylactic cerebral irradiation (18–24 Gy),
but spinal irradiation was not used. Alkylating agents were
included in the therapy for 21 patients. Alkylating agent
exposures, mean cumulative cyclophosphamide equivalent doses
(CEDs)10 and cumulative doses of anthracyclines using conversion
factor 1 for doxorubicin and 0.833 for daunorubicin are presented
in Table 1. Leukaemic inﬁltration was detected in four samples
(Figure 1a). These four patients experienced testicular relapse and
underwent a multidrug chemotherapy regimen together with
testicular irradiation at a dose of 24 Gy. An additional testis biopsy
was available for analysis after irradiation from one patient. Of the
37 boys, 23 became long-term survivors.
Testicular biopsy samples from the 37 patients were ﬁxed in
formalin, embedded in parafﬁn and stained with haematoxylin
and eosin. In each case, blind analysis of germ cell numbers was
performed in sections by an experienced examiner using a bright-
ﬁeld microscope (Labophot, Nikon, Tokyo, Japan) and spermato-
gonia per tubular cross-section (S/T) were counted. At least 25
tubular cross-sections per biopsy sample were evaluated to
achieve result validity.11 In 2 patients, 12.2 and 14.0 years of age
treated with non-alkylating agents, tissue samples showed
spermatocytes and spermatids in some tubules. However, the
morphology did not allow us to calculate exact spermatogonial
quantity; hence S/T data from these two cases were not included
in this study. In all samples, the different cell types were identiﬁed
on the basis of size, shape and location, according to Paniagua
and Nistal.12
Adult testicular volume documented by pubertal maturation
to Tanner stage 5, achievement of ﬁnal height or age 418 years
was available in connection with 23 patients (Table 1). The volume
was measured using an orchidometer (Endocrine society,
Washington DC, USA) or a ruler (Faber-Castell, Stein, Germany),
taking the mean value if both testes were evaluated. Semen
analysis was performed in 17 cases (Table 1) and consisted of
evaluation of sperm motility (a+b) and total sperm count as
described by WHO.13 Patients were considered to be azoospermic
when no spermatozoa were detected in the sample in any ﬁeld of
a double-chambered haemocytometer (Neubauer Improved, VWR
International, Stockholm, Sweden) before or after centrifugation.13
Simple and multiple regression analysis, Student’s unpaired
t-test (normally distributed variables), Mann–Whitney U-test
(non-normally distributed variables) and χ2 test were used as
appropriate to determine the relationships between spermatogo-
nial quantity, treatment characteristics and gonadal function.
Results were reported as mean± s.d. and range. Analyses were
performed using the IBM SPSS Statistics V22.0 software (IBM Corp,
Armonk, NY, USA). STATA 14.2 (StataCorp, College Station, TX,
USA) was used to explore associations in polynomial regression
functions.
Results of the analysis on 37 testicular biopsy samples showed
that numbers of S/T in samples from patients not exposed to
alkylating agents (1.6 ± 0.8, n= 19, Table 1) were within the 95%
conﬁdence intervals of normative reference values6 (Figure 1a),
following a physiological increase until the age of 6–7 years and a
plateau until the age of 11 years. In contrast, in samples from
patients exposed to alkylating agents, a signiﬁcantly lower mean
S/T value (0.4 ± 0.5, n= 16, Po0.001) was found compared with
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samples from patients treated with non-alkylating agents
(Figure 1b). Testicular irradiation resulted in complete depletion
of spermatogonia (Figure 1a).
Similarly, the tubular fertility index (TFI), the percentage of
tubular cross-sections containing spermatogonia, was signiﬁcantly
lower among patients exposed to alkylating agents compared
with the non-alkylating agent-exposed group (19%±21 and
59%±31, Po0.001), conﬁrming the results of a previous
report.14 Regression analysis showed that cumulative CEDs
44000 mg/m2 led to S/T values close to zero (Figure 1c), which
is in concordance with the results of previous reports showing that
long-term impairment of spermatogenesis and decreased fertility
is more likely after cumulative CEDs 44000 mg/m2.10,15 Patients
exposed to alkylating agents also received higher cumulative
doses of anthracyclines (Table 1). However, multiple regression
analysis conﬁrmed that the cumulative dose of alkylating agents
(B= 0.000, Po0.001) but not the dose of anthracyclines (B= 0.002,
P= 0.113) predicted spermatogonial quantity. The progression of
spermatogenesis up to spermatid stage was recorded in only 3 of
the 11 boys aged 49 years. This is in agreement with an earlier
histological report that leukaemia therapy, even without the
involvement of alkylating agents, delays the initiation of human
spermatogenesis.16 Although present in only a low number of
cases (n= 4), leukaemic inﬁltration in the testicular tissue had no
further impact on spermatogonial quantity (Figure 1a).
Among the 23 long-term survivors, at the age of 22.8 ± 5.1
(range 18–32) years and 13.1 ± 6.7 (range 0.9–21.2) years after
testicular biopsy, mean adult testicular size and sperm quality did
not differ between patients treated with and without the
alkylating agents (Table 1). No correlations were observed
between S/T or TFI and adult testicular size (r=− 0.081, P= 0.699
and r=− 0.163, P= 0.465, respectively), total sperm count
(r= 0.298, P= 0.281 and r= 0.309, P= 0.244, respectively) or sperm
motility (r= 0.222, P= 0.426 and r= 0.343, P= 0.193, respectively).
Although no correlation between TFI and total sperm count was
recorded, TFI together with S/T are important factors to determine
the risk of subfertility or infertility, as TFI reﬂects the distribution of
spermatogonia over the testis irrespective of the total number of
spermatogonia. From the patients who had testicular biopsy
acquired after the treatment with TFIo50% (not corrected
with age-matched controls), 43% were normozoospermic
(Supplementary Table 1), while from the patients with TFI450%,
62.5% recovered normal germ cell function and were considered
normozoospermic13 at the median time of 12.4 years after
stopping the treatment at the median age 20.5 years. Although
our numbers are low, this trend is in agreement with a trend
of better spermatogenic recovery for higher TFI cases described in
Figure 1. Numbers of spermatogonia per transverse tubular cross-section (S/T) of leukaemic boys exposed to chemotherapy with (red dots)
and without (blue dots) alkylating agents or irradiation (triangle). (a) S/T values after completion of induction therapy and after cessation of
ALL therapy (red and blue dots) plotted on a meta-regression ﬁt line of S/T reference values throughout healthy prepuberty*. Samples with
leukaemic inﬁltration are marked L. (b) Regression analysis of S/T values among patients up to 12 years of age. Values of S/T among patients
not exposed to alkylating agents (blue dots) show a gradual increase until the age of 6–7 years and a plateau thereafter, whereas S/T values in
patients exposed to alkylating agents (red dots) display a continuous decline from the age of 4 to 5 years. (c) Values of S/T among patients
treated with alkylating agents show a plateau at values close to zero with cumulative cyclophosphamide equivalent doses 44000 mg/m2.
*Modiﬁed from Masliukaite et al.6 Copyright (2016), with permission from Elsevier. This article is published under the terms of the Creative
Commons Attribution-NonCommercial-No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/.
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a previous report, where 45.5% of patients with TFIo50 and
88.5% of patients with TFI450% recovered normal germ cell
function at the median time 10.7 years after stopping the
treatment at the median age 18.6 years. In the latter report, all
patients with TFIo50% and no development of spermatogenesis
were treated with the alkylating agents, which is also the case in
our cohort.
Various studies in adults have shown that 470% of cancer
patients treated with low doses of alkylating agents (cumulative
CEDo7500 mg/m2) and 10–50% treated with high doses of
alkylating agents recover spermatogenesis.17,18 The fraction of
patients recovering spermatogenesis increases gradually within
5–8 years after the end of treatment followed by a plateau. Case
reports suggest that such recovery can take 420 years, and
severe delays in recovery process are expected if alkylating agent
exposure is combined with irradiation.4,19 Furthermore, one
should take into account that recovery of spermatogenesis can
only be detected from the onset of spermatogenesis at puberty.
Longer follow-up time may therefore be needed for childhood
cancer patients compared with adults. Similarly, a study reporting
semen parameters in a large cohort (214 patients)10 of childhood
cancer survivors at the median time 21 years after stopping the
treatment at the median age 29 years noted no or poor
spermatogenic recovery (azoospermia or olizogoospermia in
25% and 28% of cases, respectively). The trend of impaired
spermatogenesis was higher with cumulative CEDs44000 mg/m2.
Effectively, over half of childhood cancer survivors were shown to
experience impaired spermatogenesis as an effect of the cancer
treatment even after 20 years of follow-up. In the present study,
patients treated with alkylating (n= 7) and non-alkylating agents
(n= 10) showed no difference in total sperm count after a follow-
up period of 9–19 years (Table 1 and Supplementary Figure S1).
Although present results should be interpreted in the light of the
small sample size, they provide conﬁrmation that regeneration of
spermatogenesis, given sufﬁcient follow-up time, can be achieved
as long as the spermatogonial pool is not completely
depleted.4,7,14 Nevertheless, an extensively prolonged waiting
time for spermatogenesis recovery might compromise child-
bearing possibilities for some young couples, thus experimental
procedures of testicular biopsy cryopreservation before gonado-
toxic treatment17 could be offered to young boys who are
facing oncological treatments associated with a very high risk of
infertility.
To our knowledge, this is the ﬁrst report in which S/T
throughout acute lymphoblastic leukaemia therapy in prepuberty
has been investigated and related to follow-up measures of
testicular function. The results demonstrate that leukaemia
therapy involving alkylating agents results in long-term deple-
tion of the spermatogonial pool in some long-term survivors,
while spermatogonial quantity after therapy without alkylating
agents remains within normative reference values for prepubertal
boys. Therefore, in order to collect sufﬁcient amounts of
spermatogonial stem cells for fertility preservation as part of the
clinical research programs, a testicular biopsy sample for this
purpose needs to be acquired before initiation of alkylating
agents for some boys who later will face potentially sterilizing
cancer therapy, including allogenic haematopoietic stem cell
transplantation.
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Table 1. Descriptive statistics of testicular histology in boys who underwent testicular biopsy at the cessation of antileukaemia therapy and gonadal
function measurements after follow-up
n Exposure to non-alkylating agents, mean
± s.d. (range)
n Exposure to alkylating agents, mean
± s.d. (range)
P-value
Age at diagnosis, years 21 5.3± 2.7 (1.1–11.3) 16 7.3± 5.2 (1.7–16.1) 0.342
Age at biopsy, years 21 8.1± 2.8 (3.9–14.1) 16 9.1± 4.3 (3.6–17.5) 0.985
Exposure to cyclophosphamide (g/m2) 21 0 16 6.3± 3.5 (3.0–16.0)
Exposure to carmustine (mg/m2) 21 0 16 46.9± 84.1 (0.0–210.0)
CED (g/m2) 21 0 16 7.0 ± 3.8 (3.0–16.0)
Cumulative anthracycline dose (mg/m2) 21 55± 61 (0–120) 16 239± 146 (0–450) o0.001
Spermatogonia/cross-section 19 1.6± 0.8 (0.0–3.5) 16 0.4± 0.5 (0.0–1.7) o0.001
Fertility index (%) 21 59± 31 (0–95) 16 19± 21 (0–63) o0.001
Proportion of SCO tubules (%) 21 37± 27 (0–96) 16 81± 21 (37–100) o0.001
Histological progression of spermatogenesis
detected, n (%)
6a 2 (33%) 5a 1 (20%) 0.998
Age at follow-up (years) 15 22.9± 5.6 (18.0–32.0) 8 22.6± 5.0 (18.0–29.0) 0.828
Follow-up time from biopsy (years) 15 15.2± 6.0 (9.0–25.2) 8 10.5 ± 7.5 (0.9–19.2) 0.186
Adult testicular size (ml) 15 19.4± 7.4 (1.2–27.5) 8 19.5± 7.1 (7.3–27.0) 0.948
Total sperm count (106) 10 173.2± 175.0 (0.0–485.0) 7 50.1± 60.5 (0.0–150.0) 0.266
Motile sperm (a+b) (%) 10 43± 25 (0–83) 7 38± 26 (0–79) 0.745
Azoospermia detected, n (%) 10 1 (10%) 7 1(14%) 1.000
Abbreviations: CED, cumulative cyclophosphamide equivalent dose, SCO, Sertoli cell-only. aBoys aged 49 years.
Letters to the Editor
1462
Leukemia (2017) 1443 – 1476 © 2017 Macmillan Publishers Limited, part of Springer Nature.
1Division of Hematology-Oncology and Stem Cell Transplantation,
Children’s Hospital, University of Helsinki, Helsinki University Central
Hospital, Helsinki, Finland;
2Center for Reproductive Medicine, Women’s and Children’s Hospital,
Academic Medical Center, University of Amsterdam, Amsterdam,
The Netherlands;
3Department of Physiology, Institute of Biomedicine, University of
Turku, Turku, Finland;
4Department of Pediatrics, Turku University Hospital, Turku,
Finland and
5Department of Women’s and Children’s Health, NORDFERTIL
Research Lab Stockholm, Pediatric Endocrinology Unit, Q2:08, and
Karolinska Institutet and University Hospital, Stockholm, Sweden
E-mail: kirsi.jahnukainen@hus.ﬁ
6These authors contributed equally to this work.
REFERENCES
1 Jahnukainen K, Mitchell RT, Stukenborg JB. Testicular function and fertility pre-
servation after treatment for haematological cancer. Curr Opin Endocrinol Diabetes
Obes 2015; 22: 217–223.
2 Jahnukainen K, Ehmcke J, Quader MA, Saiful Huq M, Epperly MW, Hergenrother S
et al. Testicular recovery after irradiation differs in prepubertal and pubertal non-
human primates, and can be enhanced by autologous germ cell transplantation.
Hum Reprod 2011; 26: 1945–1954.
3 Picton HM, Wyns C, Anderson RA, Goossens E, Jahnukainen K, Kliesch S et al.
A European perspective on testicular tissue cryopreservation for fertility pre-
servation in prepubertal and adolescent boys. Hum Reprod 2015; 30: 2463–2475.
4 Anserini P, Chiodi S, Spinelli S, Costa M, Conte N, Copello F et al. Semen analysis
following allogeneic bone marrow transplantation. Additional data for evidence-
based counselling. Bone Marrow Transplant 2002; 30: 447–451.
5 WilhelmssonM, Vatanen A, Borgstrom B, Gustafsson B, Taskinen M, Saarinen-Pihkala UM
et al. Adult testicular volume predicts spermatogenetic recovery after allogeneic
HSCT in childhood and adolescence. Pediatr Blood Cancer 2014; 61: 1094–1100.
6 Masliukaite I, Hagen JM, Jahnukainen K, Stukenborg JB, Repping S, van der Veen F
et al. Establishing reference values for age-related spermatogonial quantity in
prepubertal human testis: a systematic review and meta-analysis. Fertil Steril 2016;
106: 1652.e2–1657.e2.
7 Nurmio M, Keros V, Lahteenmaki P, Salmi T, Kallajoki M, Jahnukainen K. Effect of
childhood acute lymphoblastic leukemia therapy on spermatogonia populations
and future fertility. J Clin Endocrinol Metab 2009; 94: 2119–2122.
8 Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G
et al. Improving outcome through two decades in childhood ALL in the Nordic
countries: the impact of high-dose methotrexate in the reduction of CNS
irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO).
Leukemia 2000; 14: 2267–2275.
9 Saarinen-Pihkala UM, Gustafsson G, Carlsen N, Flaegstad T, Forestier E,
Glomstein A et al. Outcome of children with high-risk acute lymphoblastic
leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central
nervous system irradiation. Pediatr Blood Cancer 2004; 42: 8–23.
10 Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM et al.
The cyclophosphamide equivalent dose as an approach for quantifying alkylating
agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood
Cancer 2014; 61: 53–67.
11 Stadtler F, Mausle E. (Morphological study on normal and disturbed prepuberal
testicular development in man (author's transl)). Verh Dtsch Ges Pathol 1971; 55:
166–172.
12 Paniagua R, Nistal M. Morphological and histometric study of human spermatogonia
from birth to the onset of puberty. J Anat 1984; 139: 535–552.
13 World Health Organization. WHO Laboratory Manual for the Examination and
Processing of Human Semen, 5th edn, World Health Organization: Geneva,
Switzerland, 2010, p 287.
14 Wallace WH, Shalet SM, Lendon M, Morris-Jones PH. Male fertility in long-term
survivors of childhood acute lymphoblastic leukaemia. Int J Androl 1991; 14:
312–319.
15 Green DM, Liu W, Kutteh WH, Ke RW, Shelton KC, Sklar CA et al. Cumulative
alkylating agent exposure and semen parameters in adult survivors of childhood
cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol 2014; 15:
1215–1223.
16 Muller J, Hertz H, Skakkebaek NE. Development of the seminiferous epithelium
during and after treatment for acute lymphoblastic leukemia in childhood. Horm
Res 1988; 30: 115–120.
17 Pryzant RM, Meistrich ML, Wilson G, Brown B, McLaughlin P. Long-term reduction
in sperm count after chemotherapy with and without radiation therapy for non-
Hodgkin's lymphomas. J Clin Oncol 1993; 11: 239–247.
18 Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G et al. Spermato-
genesis in Hodgkin's lymphoma patients: a retrospective study of semen
quality before and after different chemotherapy regimens. Hum Reprod 2016;
31: 263–272.
19 Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis
in humans. Fertil Steril 2013; 100: 1180–1186.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)
Response-adapted consolidation with bortezomib after ASCT
improves progression-free survival in newly diagnosed multiple
myeloma
Leukemia (2017) 31, 1463–1466; doi:10.1038/leu.2017.83
Frontline induction chemotherapy followed by high-dose therapy
(HDT) and autologous stem cell transplantation (ASCT) remains the
standard treatment for newly diagnosed multiple myeloma
(NDMM) in transplant-eligible patients.1 However, progression-free
survival (PFS) does often not exceed 2–3 years.1 Thus, consolidation
therapy designed to deepen and prolong responses to extend
progression-free intervals is increasingly being explored.2–4 We
present a pre-speciﬁed single dataset analysis on the combined
data of two randomized, controlled, open-label phase III studies of
bortezomib consolidation. The objective of both similarly designed
studies was to evaluate the efﬁcacy of bortezomib consolidation
after ASCT in NDMM patients aged (i) ⩽ 60 years, of whom 71% had
received a bortezomib-based induction regimen (VCD/VD; study
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